This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
IsoRay Inc. (AMEX: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, said today that the findings of a Cleveland Clinic study adds to the continuing evidence supporting the efficacy of brachytherapy. The Cleveland Clinic study compared external beam radiation, prostatectomy (the surgical removal of the prostate) and brachytherapy (internal radiation therapy). The study, which examined the treatment outcomes for 137,000 men over a five year period, found brachytherapy to have the fewest number of toxicities involving genital or urinary organs and had the lowest total cost per patient per year. The Cleveland Clinic researchers are the first to examine the quality of life and financial costs of the three most common prostate cancer treatments over a prolonged period after treatment.
IsoRay CEO Dwight Babcock said the study findings are no surprise. "The results are confirmation of what we have known at IsoRay for some time.
Brachytherapy low dose internal radiation is the most effective and cost efficient therapy available, along with having the fewest complications. Importantly, we are the only brachytherapy company with an isotope (Cesium-131) that has enough energy and the short half life needed to combat fast growing, aggressive cancers located anywhere in the body. Going forward, it is my hope that this study will serve to shift the focus back to brachytherapy as physicians receive further confirmation of its superiority."
IsoRay is the exclusive manufacturer of
Cesium-131. The pioneering brachytherapy treatment represents one of the most important advancements in internal radiation therapy in 20 years.
Cs-131 seeds deliver radiation quickly and aggressively compared to other types of internal, low dose rate radiation. Brachytherapy with Cs-131 is minimally invasive, provides higher energy, more rapidly delivers a uniform dose of radiation, and has a shorter half life (9.7 days) than other radioactive isotopes used in internal radiation therapy. The ground-breaking treatment impacts longevity and cure rates, can be performed outside a hospital setting, and results in a patient's faster return to normal activities.
Babcock says he strongly believes the expected upcoming release of IsoRay's 5 year data on the use of Cesium-131 to treat prostate cancer will provide further compelling evidence for doctors and the patients they treat regarding the choice of Cesium-131. "While for quite some time we have known our isotope Cesium-131 has been performing better than other treatments, we now have our 5 year data being peer reviewed, providing factual evidence supporting the claims of independent medical professionals that we have the best performing brachytherapy seed for prostate cancer on the market. Current data already proves we are superior in both energy and having patients return to baseline faster following treatment." Babcock says that he also expects a number of significant developments in the months ahead regarding further progress in current initiatives and ongoing discussions relative to the application of Cesium-131 for treating cancers in other body sites including breast, pancreatic, and esophageal cancers.